Immunological Alterations due to Hemodialysis Might Interfere with Early Complications in Renal Transplantation

Table 1

Baseline characteristics.

Patients	Sex category (m: male/f: female)	Age (years)	Blood group^1	Kidney disease^2	HbA1c (%)	C-reactive protein (g/l)	Time on dialysis (months)	Cumulative weekly dialysis dose (hours)	Anticoagulation^3		Residual diuresis^4	Serum creatinine (μmol/l)	Blood urea nitrogen (BUN) (mmol/l)	Anti-Hbs antibodies (mIU/ml)^5	Number of previous transplantations	Panel reactive antibodies (%)
1	m	32	A (+)	2	5.7	7.1	55	14.25	UFH	1.24	0	836	12.32	1	1	4
2	f	66	0 (+)	0	5.1	13.1	60	8	UFH	1.43	1	418	10.22	2	0	0
3	m	37	A (+)	0	5.3	19	47	14	UFH	1.22	1	1123	10.59	2	0	0
4	m	36	0 (-)	2	5.2	2	144	15	LMWH	1.11	0	1296	12.41	2	0	0
5	m	46	A (+)	1	5	8.5	142	13	LMWH	1.59	0	1275	14.98	0	1	0
6	m	61	A (+)	0	5.8	13.6	27	12	UFH	1.02	1	778	7.84	2	0	0
7	m	55	0 (-)	0	4.8	12.9	97	14	LMWH	1.54	1	1193	14.42	0	0	0
8	f	22	A (+)	0	5.2	1.2	45	12	UFH	1.86	0	1049	11.57	2	0	0
9	f	49	0 (-)	0	4.9	3	88	15	UFH	2.14	1	871	10.13	2	0	18
10	f	57	A (+)	0	4.8	2.7	48	13	Ar	1.49	0	1061	9.66	2	0	25
11	m	28	A (-)	0	4.6	8.9	44	15	UFH	1.12	0	1469	12.65	2	1	47
12	f	60	B (+)	3	4.5	4.3	45	15	UFH	1.84	1	223	2.29	0	0	70
13	f	53	B (+)	0	5.2	21.8	111	14	UFH	1.74	1	964	11.43	1	1	78
14	f	38	0 (+)	3	8.9	1	33	12	UFH	1.26	0	849	9.24	0	0	78
15	f	56	B (+)	2	5.6	0.9	68	13	UFH	1.61	0	1069	13.63	2	1	85
Median		49			5.2	7.1	55	14		1.49		1049	11.43			9

. 14 Caucasians except patient no. 15 (Vietnamese). Furthermore, all patients received treatment with iron and recombinant erythropoietin. ¹Blood group: (-): Rhesus negative; (+): Rhesus positive. ²0: analgetics, cisplatine, ischaemia, orellanus, nephrosclerosis, pyelonephritis, CKD5D (unknown reasons), shrinkle kidneys, adult dominant polycystic kidney disease. 1: Alport syndrome; 2: focal segmental glomerulosclerosis; 3: diabetes mellitus. ³UFH: unfractionated heparin; LMWH: low molecular weight heparin; Ar: argatroban. ⁴0: ≤500 ml; 1: >500 ml. ⁵0: <10; 1: 10-100; 2: >100.